The news is directly about Phathom Pharmaceuticals. Goldman Sachs, a major financial institution, has maintained a Neutral rating on the company, indicating no significant changes in the company's performance. However, the increase in price target from $9 to $10 suggests a slightly positive outlook, but it's not significant enough to predict a strong upward movement in the short term.